Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

LAMEA Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026

Published by KBV Research Product code 988480
Published Content info 97 Pages
Delivery time: 1-2 business days
Price
Back to Top
LAMEA Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026
Published: January 29, 2021 Content info: 97 Pages
Description

The Latin America, Middle East and Africa Antibiotics Market would witness market growth of 6.2% CAGR during the forecast period (2020-2026).

Antibiotics are basically a combination of medicines that helps in curing infection caused by germs, bacteria, and some parasites. It kills all the infection-causing microorganisms. From the beginning of infectious diseases, till now, there have been numerous incidents of chronic and infectious diseases that are leading the growth of the antibiotic market. The growing prevalence of infectious diseases provides great opportunities for the companies, as antibiotics help in curing these infectious diseases. Therefore, it further accelerates the growth of the market.

The increasing incidents of chronic and infectious diseases around the globe and the properties of antibiotics to treat the broad spectrum of bacterial infections will propel the growth of the antibiotic market. There are many companies that are implementing some strategic plans of collaborative development programs to cut down their expenses. These plans will help the companies to develop more molecules. Further, the public-private collaborations, where funds and unique R&D approaches are adopted by public bodies and antibiotics manufacturers, will assist the creation of the latest and modern pipeline products.

The collaborative development efforts help the companies to widen up their range of products. It also encourages them to develop innovative and advanced solutions, which further support the growth of the antibiotic market.

Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.

Scope of the Study

Market Segments covered in the Report:

By Action Mechanism

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors,
  • Mycolic Acid Inhibitors

By Drug Class

  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolides
  • Carbapenem
  • Aminoglycosides
  • Sulfonamides,
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

  • GlaxoSmithKline PLC (GSK)
  • Johnson and Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi S.A.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 LAMEA Antibiotics Market, by Action Mechanism
    • 1.4.2 LAMEA Antibiotics Market, by Drug Class
    • 1.4.3 LAMEA Antibiotics Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Approvals
    • 3.2.4 Acquisition and Mergers
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
    • 3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct - 2020, Jul) Leading Players

Chapter 4. LAMEA Antibiotics Market by Action Mechanism

  • 4.1 LAMEA Cell Wall Synthesis Inhibitors Market by Country
  • 4.2 LAMEA Protein Synthesis Inhibitors Market by Country
  • 4.3 LAMEA DNA Synthesis Inhibitors Market by Country
  • 4.4 LAMEA RNA Synthesis Inhibitors Market by Country
  • 4.5 LAMEA Others Market by Country

Chapter 5. LAMEA Antibiotics Market by Drug Class

  • 5.1 LAMEA Cephalosporin Market by Country
  • 5.2 LAMEA Penicillin Market by Country
  • 5.3 LAMEA Fluoroquinolone Market by Country
  • 5.4 LAMEA Macrolides Market by Country
  • 5.5 LAMEA Carbapenem Market by Country
  • 5.6 LAMEA Aminoglycosides Market by Country
  • 5.7 LAMEA Sulfonamides Market by Country
  • 5.8 LAMEA Others Market by Country

Chapter 6. LAMEA Antibiotics Market by Country

  • 6.1 Brazil Antibiotics Market
    • 6.1.1 Brazil Antibiotics Market by Action Mechanism
    • 6.1.2 Brazil Antibiotics Market by Drug Class
  • 6.2 Argentina Antibiotics Market
    • 6.2.1 Argentina Antibiotics Market by Action Mechanism
    • 6.2.2 Argentina Antibiotics Market by Drug Class
  • 6.3 UAE Antibiotics Market
    • 6.3.1 UAE Antibiotics Market by Action Mechanism
    • 6.3.2 UAE Antibiotics Market by Drug Class
  • 6.4 Saudi Arabia Antibiotics Market
    • 6.4.1 Saudi Arabia Antibiotics Market by Action Mechanism
    • 6.4.2 Saudi Arabia Antibiotics Market by Drug Class
  • 6.5 South Africa Antibiotics Market
    • 6.5.1 South Africa Antibiotics Market by Action Mechanism
    • 6.5.2 South Africa Antibiotics Market by Drug Class
  • 6.6 Nigeria Antibiotics Market
    • 6.6.1 Nigeria Antibiotics Market by Action Mechanism
    • 6.6.2 Nigeria Antibiotics Market by Drug Class
  • 6.7 Rest of LAMEA Antibiotics Market
    • 6.7.1 Rest of LAMEA Antibiotics Market by Action Mechanism
    • 6.7.2 Rest of LAMEA Antibiotics Market by Drug Class

Chapter 7. Company Profiles

  • 7.1 GlaxoSmithKline PLC (GSK)
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental and Regional Analysis
    • 7.1.4 Research & Development Expense
  • 7.2 Johnson and Johnson
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental &Regional Analysis
    • 7.2.4 Research & Development Expenses
    • 7.2.5 Recent strategies and developments:
      • 7.2.5.1 Acquisition and Mergers:
  • 7.3 Merck & Co., Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expenses
    • 7.3.1 Recent strategies and developments:
      • 7.3.1.1 Product Launches and Product Expansions:
      • 7.3.1.2 Approvals:
  • 7.4 Pfizer, Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Segmental and Regional Analysis
    • 7.4.4 Recent strategies and developments:
      • 7.4.4.1 Acquisition and Mergers:
      • 7.4.4.2 Product Launches and Product Expansions:
  • 7.5 Bayer AG
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental and Regional Analysis
    • 7.5.4 Research & Development Expense
  • 7.6 Novartis AG
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Segmental and Regional Analysis
    • 7.6.4 Recent strategies and developments:
      • 7.6.4.1 Partnerships, Collaborations, and Agreements:
  • 7.7 Sanofi S.A.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
    • 7.7.5 Recent strategies and developments:
      • 7.7.5.1 Acquisition and Mergers:
      • 7.7.5.2 Partnerships, Collaborations, and Agreements:
  • 7.8 Abbott Laboratories
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 F. Hoffmann-La Roche Ltd.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Segmental and Regional Analysis
    • 7.9.4 Research & Development Expense
    • 7.9.5 Recent strategies and developments:
      • 7.9.5.1 Partnerships, Collaborations, and Agreements:
  • 7.10. Eli Lilly and Company
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Regional Analysis
    • 7.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 LAMEA Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 2 LAMEA Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Antibiotics Market
  • TABLE 4 Product Launches And Product Expansions- Antibiotics Market
  • TABLE 5 Approvals- Antibiotics Market
  • TABLE 6 Acquisition and Mergers- Antibiotics Market
  • TABLE 7 LAMEA Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 8 LAMEA Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 9 LAMEA Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 10 LAMEA Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 11 LAMEA Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 12 LAMEA Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 13 LAMEA DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 14 LAMEA DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 15 LAMEA RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 16 LAMEA RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 17 LAMEA Others Market by Country, 2016 - 2019, USD Million
  • TABLE 18 LAMEA Others Market by Country, 2020 - 2026, USD Million
  • TABLE 19 LAMEA Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 20 LAMEA Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 21 LAMEA Cephalosporin Market by Country, 2016 - 2019, USD Million
  • TABLE 22 LAMEA Cephalosporin Market by Country, 2020 - 2026, USD Million
  • TABLE 23 LAMEA Penicillin Market by Country, 2016 - 2019, USD Million
  • TABLE 24 LAMEA Penicillin Market by Country, 2020 - 2026, USD Million
  • TABLE 25 LAMEA Fluoroquinolone Market by Country, 2016 - 2019, USD Million
  • TABLE 26 LAMEA Fluoroquinolone Market by Country, 2020 - 2026, USD Million
  • TABLE 27 LAMEA Macrolides Market by Country, 2016 - 2019, USD Million
  • TABLE 28 LAMEA Macrolides Market by Country, 2020 - 2026, USD Million
  • TABLE 29 LAMEA Carbapenem Market by Country, 2016 - 2019, USD Million
  • TABLE 30 LAMEA Carbapenem Market by Country, 2020 - 2026, USD Million
  • TABLE 31 LAMEA Aminoglycosides Market by Country, 2016 - 2019, USD Million
  • TABLE 32 LAMEA Aminoglycosides Market by Country, 2020 - 2026, USD Million
  • TABLE 33 LAMEA Sulfonamides Market by Country, 2016 - 2019, USD Million
  • TABLE 34 LAMEA Sulfonamides Market by Country, 2020 - 2026, USD Million
  • TABLE 35 LAMEA Others Market by Country, 2016 - 2019, USD Million
  • TABLE 36 LAMEA Others Market by Country, 2020 - 2026, USD Million
  • TABLE 37 LAMEA Antibiotics Market by Country, 2016 - 2019, USD Million
  • TABLE 38 LAMEA Antibiotics Market by Country, 2020 - 2026, USD Million
  • TABLE 39 Brazil Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 40 Brazil Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 41 Brazil Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 42 Brazil Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 43 Brazil Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 44 Brazil Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 45 Argentina Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 46 Argentina Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 47 Argentina Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 48 Argentina Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 49 Argentina Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 50 Argentina Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 51 UAE Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 52 UAE Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 53 UAE Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 54 UAE Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 55 UAE Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 56 UAE Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 57 Saudi Arabia Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 58 Saudi Arabia Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 59 Saudi Arabia Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 60 Saudi Arabia Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 61 Saudi Arabia Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 62 Saudi Arabia Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 63 South Africa Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 64 South Africa Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 65 South Africa Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 66 South Africa Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 67 South Africa Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 68 South Africa Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 69 Nigeria Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 70 Nigeria Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 71 Nigeria Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 72 Nigeria Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 73 Nigeria Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 74 Nigeria Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 75 Rest of LAMEA Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 76 Rest of LAMEA Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 77 Rest of LAMEA Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 78 Rest of LAMEA Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 79 Rest of LAMEA Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 80 Rest of LAMEA Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 81 Key Information - GlaxoSmithKline PLC (GSK)
  • TABLE 82 Key information -Johnson and Johnson
  • TABLE 83 key information - Merck & Co., Inc.
  • TABLE 84 Key Information - Pfizer, Inc.
  • TABLE 85 Key Information - Bayer AG
  • TABLE 86 Key Information - Novartis AG
  • TABLE 87 Key Information - Sanofi S.A.
  • TABLE 88 Key Information - Abbott Laboratories
  • TABLE 89 key information - F. Hoffmann-La Roche Ltd.
  • TABLE 90 Key Information - Eli Lilly and Company

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2016-2020)
  • FIG 4 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct - 2020, Jul) Leading Players
  • FIG 5 Recent strategies and developments: Merck & Co., Inc.
  • FIG 6 Recent strategies and developments: Pfizer, Inc.
  • FIG 7 Recent strategies and developments: Sanofi S.A.
Back to Top